Quick Search  in all journalsin this journalin this issue Journals Home Drugs of Today Issues Drugs of Today Policies & Guidelines Subscribe Permissions My Profile Contact Us Shopping Cart Purchase History

	Drugs of Today		Register or sign in
	Drugs Today 2010, 46(2): 91 ISSN 1699-3993 Copyright 2010 Clarivate CCC: 1699-3993 DOI: 10.1358/dot.2010.46.2.1439260
	Pralatrexate - From bench to bedside Zain, J.M., Marchi, E.
	Pralatrexate (PDX, 10-propargyl 10-deazaaminopterin) is an exciting new chemotherapeutic agent with promising activity in T-cell lymphomas and non-small cell lung cancer. It has been granted approval by the Food and Drug administration (FDA) for use in the treatment of relapsed and refractory peripheral T-cell lymphomas (PTCL). Pralatrexate belongs to a class of antineoplastic agents known as antifolates that also include methotrexate, pemetrexed and ralitrexed. Pralatrexate was rationally designed to have high affinity for the one carbon-reduced folate carrier (RFC-1) which leads to better cellular internalization of the drug and a greater antitumor effect than methotrexate. The following monograph is a story of the development of this drug in a systematic fashion from the bench to the bedside. Full Text: HTML, PDF

	© Clarivate. All rights reserved.
	Copyright Notice	Terms of Use	Privacy Statement	Cookie Policy